CHOD/BVAM Chemotherapy and Whole-Brain Radiotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma
- Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota (United States)
- Division of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota (United States)
- Department of Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota (United States)
- Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota (United States)
- Department of Neuro-Oncology, The M.D. Anderson Cancer Center, Houston, Texas (United States)
- Oschner CCOP, New Orleans, Louisiana (United States)
- Iowa Oncology Research Association CCOP, Des Moines, Iowa (United States)
- CentraCare Clinic, St. Cloud, Minnesota (United States)
- Colorado Cancer Research Program, Denver, Colorado (United States)
Purpose: To assess the efficacy and toxicity of chemotherapy consisting of cyclophosphamide, doxorubicin (Adriamycin), vincristine, and dexamethasone (CHOD) plus bis-chloronitrosourea (BCNU), cytosine arabinoside, and methotrexate (BVAM) followed by whole-brain irradiation (WBRT) for patients with primary central nervous system lymphoma (PCNSL). Methods and Materials: Patients 70 years old and younger with newly diagnosed, biopsy-proven PCNSL received one cycle of CHOD followed by two cycles of BVAM. Patients then received WBRT, 30.6 Gy, if a complete response was evoked, or 50.4 Gy if the response was less than complete; both doses were given in 1.8-Gy daily fractions. The primary efficacy endpoint was 1-year survival. Results: Thirty-six patients (19 men, 17 women) enrolled between 1995 and 2000. Median age was 60.5 years (range, 34 to 69 years). Thirty (83%) patients had baseline Eastern Cooperative Oncology Group performance scores of 0 to 1. All 36 patients were eligible for survival and response evaluations. Median time to progression was 12.3 months, and median survival was 18.5 months. The percentages of patients alive at 1, 2, and 3 years were 64%, 36%, and 33%, respectively. The best response was complete response in 10 patients and immediate progression in 7 patients. Ten (28%) patients had at least one grade 3 or higher neurologic toxicity. Conclusions: This regimen did improve the survival of PCNSL patients but also caused substantial toxicity. The improvement in survival is less than that reported with high-dose methotrexate-based therapies.
- OSTI ID:
- 21587738
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 81, Issue 2; Other Information: DOI: 10.1016/j.ijrobp.2010.06.002; PII: S0360-3016(10)00786-8; Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Involved-Node Proton Therapy in Combined Modality Therapy for Hodgkin Lymphoma: Results of a Phase 2 Study
Multimodality therapy for medulloblastoma. [Efficacy and complications]
Related Subjects
BIOPSY
BRAIN
CHEMOTHERAPY
CYTOSINE
DEXAMETHASONE
DOXORUBICIN
ENDOXAN
IRRADIATION
LYMPHOMAS
METHOTREXATE
RADIATION DOSES
RADIOTHERAPY
TOXICITY
ADRENAL HORMONES
ALKYLATING AGENTS
AMINES
ANTIBIOTICS
ANTI-INFECTIVE AGENTS
ANTIMETABOLITES
ANTINEOPLASTIC DRUGS
AZINES
BODY
CENTRAL NERVOUS SYSTEM
CORTICOSTEROIDS
DIAGNOSTIC TECHNIQUES
DISEASES
DOSES
DRUGS
GLUCOCORTICOIDS
HETEROCYCLIC COMPOUNDS
HORMONES
HYDROXY COMPOUNDS
IMMUNE SYSTEM DISEASES
IMMUNOSUPPRESSIVE DRUGS
KETONES
MEDICINE
NEOPLASMS
NERVOUS SYSTEM
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANIC OXYGEN COMPOUNDS
ORGANS
PREGNANES
PYRIMIDINES
RADIOLOGY
STEROID HORMONES
STEROIDS
THERAPY